Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer

Author:

Cho Byoung Chul,Chiu Chao-Hua,Massarelli Erminia,Buchschacher Gary L.,Goto Koichi,Overbeck Tobias R.,Loong Herbert H.F.,Chee Cheng E.,Garrido Pilar,Dong Xiaorong,Fan Yun,Lu Shun,Schwemmers Sven,Bordogna Walter,Zeuner Harald,Osborne Stuart,John ThomasORCID

Funder

F. Hoffmann-La Roche

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference29 articles.

1. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study;Mok;Ann. Oncol.,2020

2. Postoperative chemotherapy use and outcomes from ADAURA: osimertinib as adjuvant therapy for resected EGFR-mutated NSCLC;Wu;J. Thorac. Oncol.,2022

3. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001;Shaw;Ann. Oncol.,2019

4. Updated integrated analysis of the efficacy and safety of entrectinib in patients With NTRK fusion-positive solid tumors;Demetri;Clin. Cancer Res.,2022

5. Clinicopathologic features of non-small-cell lung cancer harboring an NTRK gene fusion;Farago;JCO Precis. Oncol.,2018

全球学者库

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"全球学者库"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前全球学者库共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2023 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3